Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Cho, Hyun Jong ^a   Yoon, In Soo ^b  

^a Kangwon National University   (South Korea)

^b Mokpo National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALLICIN; ALLIIN; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2C11; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; CYTOCHROME P450 4A1; DIALLYL DISULFIDE; GARLIC EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE DERIVATIVE; GINKGOLIDE J; GINKGOLIDE M; MULTIDRUG RESISTANCE PROTEIN; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLACK PEPPER; CAMELLIA SINENSIS; CURCUMA LONGA; DRUG STRUCTURE; GARLIC; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA GLABRA; HERB DRUG INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONION; PLANT ROOT; PRIORITY JOURNAL; REVIEW; ROSEMARY;

EID: 84921536503     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/736431     Document Type: Review

References (99)

1. R. Hermann and O. von Richter, and quot;Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions, and " Planta Medica, vol. 78, no. 13, pp. 1458-1477, 2012.
2. M. de Lima Toccafondo Vieira and S.-M. Huang, and quot;Botanicaldrug interactions: a scientific perspective, and " Planta Medica, vol. 78, no. 13, pp. 1400-1415, 2012.
3. S. Bent, and quot;Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center, and " Journal of General Internal Medicine, vol. 23, no. 6, pp. 854-859, 2008.
4. A. Bardia, N. L. Nisly, M. B. Zimmerman, B. M. Gryzlak, and R. B. Wallace, and quot;Use of herbs among adults based on evidencebased indications: Findings fromthe NationalHealth Interview Survey, and " Mayo Clinic Proceedings, vol. 82, no. 5, pp. 561-566, 2007.
5. S.-B. Kim, I.-S. Yoon, K.-S. Kim et al., and quot;In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome P450-mediated drug metabolism, and " Planta Medica, vol. 80, no. 7, pp. 561-567, 2014.
6. S. Zhou, Y. Gao, W. Jiang, M. Huang, A. Xu, and J. W. Paxton, and quot;Interactions of herbs with cytochrome P450, and " DrugMetabolism Reviews, vol. 35, no. 1, pp. 35-98, 2003.
7. O. Pelkonen, M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, and H. Raunio, and quot;Inhibition and induction of human cytochrome P450 enzymes: current status, and " Archives of Toxicology, vol. 82, no. 10, pp. 667-715, 2008.
8. J.-J. Wu, C.-Z. Ai, Y. Liu et al., and quot;Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes, and " Current Drug Metabolism, vol. 13, no. 5, pp. 599-614, 2012.
9. A. H. Schinkel and J. W. Jonker, and quot;Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, and " Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 3-29, 2003.
10. S. Zhou, L. Y. Lim, and B. Chowbay, and quot;Herbalmodulation of Pglycoprotein, and " Drug Metabolism Reviews, vol. 36, no. 1, pp. 57-104, 2004.
11. International Transporter Consortium, K. M. Giacomini, S. M. Huang et al., and quot;Membrane transporters in drug development, and " Nature Reviews Drug Discovery, vol. 9, no. 3, pp. 215-236, 2010.
12. J.-E. Kim, I.-S. Yoon, H.-J. Cho, D.-H. Kim, Y.-H. Choi, and D.-D. Kim, and quot;Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: improved intestinal paracellular absorption and alleviated cardiotoxicity, and " International Journal of Pharmaceutics, vol. 464, no. 1-2, pp. 117-126, 2014.
13. J.-E. Kim, H.-J. Cho, J. S. Kim et al., and quot;The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin, and " Xenobiotica, vol. 43, no. 7, pp. 579-591, 2013.
14. S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens, and quot;Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein), and " Oncologist, vol. 12, no. 8, pp. 927-941, 2007.
15. F. V. DeFeudis and K. Drieu, and quot;Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications, and " Current Drug Targets, vol. 1, no. 1, pp. 25-58, 2000.
16. D. J. McKenna, K. Jones, and K. Hughes, and quot;Efficacy, safety, and use of ginkgo biloga in clinical and preclinical applications, and " Alternative Therapies in Health and Medicine, vol. 7, no. 5, pp. 70-86, 88-90, 2001.
17. Y. Tang, F. Lou, J. Wang, Y. Li, and S. Zhuang, and quot;Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba, and " Phytochemistry, vol. 58, no. 8, pp. 1251-1256, 2001.
18. K. Shinozuka, K. Umegaki, Y. Kubota et al., and quot;Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats, and " Life Sciences, vol. 70, no. 23, pp. 2783-2792, 2002.
19. J. Tang, J. Sun, Y. Zhang, L. Li, F. Cui, and Z. He, and quot;Herb-drug interactions: effect ofGinkgo biloba extract on the pharmacokinetics of theophylline in rats, and " Food and Chemical Toxicology, vol. 45, no. 12, pp. 2441-2445, 2007.
20. C. Gaudineau, R. Beckerman, S. Welbourn, and K. Auclair, and quot;Inhibition of human P450 enzymes bymultiple constituents of the Ginkgo biloba extract, and " Biochemical and Biophysical Research Communications, vol. 318, no. 4, pp. 1072-1078, 2004.
21. S. M. Robertson, R. T. Davey, J. Voell, E. Formentini, R. M. Alfaro, and S. R. Penzak, and quot;Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects, and " CurrentMedical Research and Opinion, vol. 24, no. 2, pp. 591-599, 2008.
22. B. H. Hellum and O. G. Nilsen, and quot;In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products, and " Basic and Clinical Pharmacology&Toxicology, vol. 102, no. 5, pp. 466-475, 2008.
23. L. Fan, G.-Y. Tao, G. Wang et al., and quot;Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers, and " Annals of Pharmacotherapy, vol. 43, no. 5, pp. 944-949, 2009.
24. L. L. von Moltke, J. L. Weemhoff, E. Bedir et al., and quot;Inhibition of human cytochromes P450 by components of Ginkgo biloba, and " Journal of Pharmacy and Pharmacology, vol. 56, no. 8, pp. 1039-1044, 2004.
25. Y.-H. Liu, S.-L. Mo, H.-C. Bi et al., and quot;Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study, and " Xenobiotica, vol. 41, no. 4, pp. 259-280, 2011.
26. K. Rahman, and quot;Historical perspective on garlic and cardiovascular disease, and " The Journal of Nutrition, vol. 131, supplement 3, pp. 977S-979S, 2001.
27. B. S. Joshi and P. N. Kaul, and quot;Alternative medicine: herbal drugs and their critical appraisal part I, and " Progress inDrug Research, vol. 56, pp. 1-76, 2001.
28. C. Colalto, and quot;Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment, and " Pharmacological Research, vol. 62, no. 3, pp. 207-227, 2010.
29. H. Amagase, B. L. Petesch, H. Matsuura, S. Kasuga, and Y. Itakura, and quot;Intake of garlic and its bioactive components, and " The Journal of Nutrition, vol. 131, no. 3, pp. 955S-962S, 2001.
30. R. Kishimoto, M. Ueda, H. Yoshinaga, K. Goda, and S.-S. Park, and quot;Combined effects of ethanol and garlic on hepatic ethanol metabolism in mice, and " Journal of Nutritional Science and Vitaminology, vol. 45, no. 3, pp. 275-286, 1999.
31. B. C. Foster, M. S. Foster, S. Vandenhoek et al., and quot;An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic, and " Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 2, pp. 176-184, 2001.
32. L. S. Lee, A. S. A. Andrade, and C. Flexner, and quot;Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects, and " Clinical Infectious Diseases, vol. 43, no. 8, pp. 1052-1059, 2006.
33. Y. H. Choi, Y.-W. Chin, and Y. G. Kim, and quot;Herb-drug interactions: focus on metabolic enzymes and transporters, and " Archives of Pharmacal Research, vol. 34, no. 11, pp. 1843-1863, 2011.
34. M. L. Dupuis, M. Flego, A. Molinari, and M. Cianfriglia, and quot;Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEM cells, and " HIV Medicine, vol. 4, no. 4, pp. 338-345, 2003.
35. L. Jin and T. A. Baillie, and quot;Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats, and " Chemical Research in Toxicology, vol. 10, no. 3, pp. 318-327, 1997.
36. C. Teyssier, L. Guenot, M. Suschetet, and M.-H. Siess, and quot;Metabolism of diallyl disulfide by human liver microsomal cytochromes P-450 and flavin-containing monooxygenases, and " Drug Metabolism and Disposition, vol. 27, no. 7, pp. 835-841, 1999.
37. C. Y. Yang, P. D. L. Chao, Y. C. Hou, S. Y. Tsai, K. C. Wen, and S. L. Hsiu, and quot;Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats, and " Food and Chemical Toxicology, vol. 44, no. 9, pp. 1572-1578, 2006.
38. D. Saleheen, S. A. Ali, and M. M. Yasinzai, and quot;Antileishmanial activity of aqueous onion extract in vitro, and " Fitoterapia, vol. 75, no. 1, pp. 9-13, 2004.
39. K. E. Campos, Y. S. Diniz, A. C. Cataneo, L. A. Faine, M. J. Q. F. Alves, and E. L. B. Novelli, and quot;Hypoglycaemic and antioxidant effects of onion, Allium cepa: dietary onion addition, antioxidant activity and hypoglycaemic effects on diabetic rats, and " International Journal of Food Sciences and Nutrition, vol. 54, no. 3, pp. 241-246, 2003.
40. J. Patel, B. Buddha, S. Dey, D. Pal, and A. K. Mitra, and quot;In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity, and " American Journal ofTherapeutics, vol. 11, no. 4, pp. 262-277, 2004.
41. P. P. Maliakal, P. F. Coville, and S. Wanwimolruk, and quot;Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats, and " Journal of Pharmacy and Pharmacology, vol. 53, no. 4, pp. 569-577, 2001.
42. A. Bu-Abbas, M. N. Clifford, R. Walker, and C. Ioannides, and quot;Modulation of hepatic cytochrome P450 activity and carcinogen bioactivation by black and decaffeinated black tea, and " Environmental Toxicology and Pharmacology, vol. 7, no. 1, pp. 41-47, 1999.
43. M. Nishikawa, N. Ariyoshi, A. Kotani et al., and quot;Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam, and " Drug Metabolism and Pharmacokinetics, vol. 19, no. 4, pp. 280-289, 2004.
44. M. I. Netsch, H. Gutmann, C. B. Schmidlin, C. Aydogan, and J. Drewe, and quot;Induction of CYP1A by green tea extract in human intestinal cell lines, and " Planta Medica, vol. 72, no. 6, pp. 514-520, 2006.
45. J. Jodoin, M. Demeule, and R. Béliveau, and quot;Inhibition of themultidrug resistance P-glycoprotein activity by green tea polyphenols, and " Biochimica et Biophysica Acta, vol. 1542, no. 1-3, pp. 149-159, 2002.
46. Y. Mei, F. Qian, D. Wei, and J. Liu, and quot;Reversal of cancermultidrug resistance by green tea polyphenols, and " The Journal of Pharmacy and Pharmacology, vol. 56, no. 10, pp. 1307-1314, 2004.
47. D. A. Balentine, S. A. Wiseman, and L. C. M. Bouwens, and quot;The chemistry of tea flavonoids, and " Critical Reviews in Food Science and Nutrition, vol. 37, no. 8, pp. 693-704, 1997.
48. J. D. Lambert and C. S. Yang, and quot;Cancer chemopreventive activity and bioavailability of tea and tea polyphenols, and " Mutation Research, vol. 523-524, pp. 201-208, 2003.
49. M. Antonello, D. Montemurro, M. Bolognesi et al., and quot;Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts, and " The American Journal of Hypertension, vol. 20, no. 12, pp. 1321-1328, 2007.
50. I. Papparella, G. Ceolotto, D. Montemurro et al., and quot;Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway, and " The Journal of Nutrition, vol. 138, no. 9, pp. 1596-1601, 2008.
51. Y.-W. Chin, H.-A. Jung, Y. Liu et al., and quot;Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra), and " Journal of Agricultural and Food Chemistry, vol. 55, no. 12, pp. 4691-4697, 2007.
52. M. N. Asl and H. Hosseinzadeh, and quot;Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds, and " Phytotherapy Research, vol. 22, no. 6, pp. 709-724, 2008.
53. Y. Fujisawa, M. Sakamoto, M. Matsushita, T. Fujita, and K. Nishioka, and quot;Glycyrrhizin inhibits the lytic pathway of complement-possiblemechanismof its anti-inflammatory effect on liver cells in viral hepatitis, and " Microbiology and Immunology, vol. 44, no. 9, pp. 799-804, 2000.
54. M. Paolini, L. Pozzetti, A. Sapone, and G. Cantelli-Forti, and quot;Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases, and " Life Sciences, vol. 62, no. 6, pp. 571-582, 1998.
55. J.-H. Tu, Y.-J. He, Y. Chen et al., and quot;Effect of glycyrrhizin on the activity of CYP3A enzyme in humans, and " European Journal of Clinical Pharmacology, vol. 66, no. 8, pp. 805-810, 2010.
56. T. Nabekura, T. Yamaki, K. Ueno, and S. Kitagawa, and quot;Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals, and " Cancer Chemotherapy and Pharmacology, vol. 62, no. 5, pp. 867-873, 2008.
57. F. Borrelli, R. Capasso, A. Pinto, and A. A. Izzo, and quot;Inhibitory effect of ginger (Zingiber officinale) on rat ilealmotility in vitro, and " Life Sciences, vol. 74, no. 23, pp. 2889-2896, 2004.
58. M. N. Ghayur and A. H. Gilani, and quot;Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders, and " Digestive Diseases and Sciences, vol. 50, no. 10, pp. 1889-1897, 2005.
59. A. S. El-Sharaky, A. A. Newairy, M. A. Kamel, and S. M. Eweda, and quot;Protective effect of ginger extract against bromobenzeneinduced hepatotoxicity in male rats, and " Food and Chemical Toxicology, vol. 47, no. 7, pp. 1584-1590, 2009.
60. B. H. Ali, G. Blunden, M. O. Tanira, and A. Nemmar, and quot;Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research, and " Food and Chemical Toxicology, vol. 46, no. 2, pp. 409-420, 2008.
61. Y. Kimura, H. Ito, and T. Hatano, and quot;Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity, and " Biological and Pharmaceutical Bulletin, vol. 33, no. 12, pp. 1977-1982, 2010.
62. I. S. Kim, S. Y. Kim, and H. H. Yoo, and quot;Effects of an aqueousethanolic extract of ginger on cytochrome P450 enzymemediated drug metabolism, and " Pharmazie, vol. 67, no. 12, pp. 1007-1009, 2012.
63. T. Nabekura, S. Kamiyama, and S. Kitagawa, and quot;Effects of dietary chemopreventive phytochemicals on P-glycoprotein function, and " Biochemical and Biophysical Research Communications, vol. 327, no. 3, pp. 866-870, 2005.
64. S. Pandit, P. K. Mukherjee, K. Mukherjee et al., and quot;Cytochrome P450 inhibitory potential of selected Indian spices-possible food drug interaction, and " Food Research International, vol. 45, no. 1, pp. 69-74, 2012.
65. K. Srinivasan, and quot;Black pepper and its pungent principle-piperine: a review of diverse physiological effects, and " Critical Reviews in Food Science and Nutrition, vol. 47, no. 8, pp. 735-748, 2007.
66. S. Bajad, K. L. Bedi, A. K. Singla, and R. K. Johri, and quot;Antidiarrhoeal activity of piperine in mice, and " Planta Medica, vol. 67, no. 3, pp. 284-287, 2001.
67. Y.-F. Bai and H. Xu, and quot;Protective action of piperine against experimental gastric ulcer, and " Acta Pharmacologica Sinica, vol. 21, no. 4, pp. 357-359, 2000.
68. J. R. Stöhr, P.-G. Xiao, and R. Bauer, and quot;Constituents of Chinese Piper species and their inhibitory activity on prostaglandin and leukotriene biosynthesis in vitro, and " Journal of Ethnopharmacology, vol. 75, no. 2-3, pp. 133-139, 2001.
69. R. Mittal and R. L. Gupta, and quot;In vitro antioxidant activity of piperine, and " Methods and Findings in Experimental and Clinical Pharmacology, vol. 22, no. 5, pp. 271-274, 2000.
70. Z. Lin, J. R. S. Hoult, D. C. Bennett, and A. Raman, and quot;Stimulation ofmousemelanocyte proliferation by Piper nigrumfruit extract and its main alkaloid, piperine, and " PlantaMedica, vol. 65, no. 7, pp. 600-603, 1999.
71. S. Bajad, K. L. Bedi, A. K. Singla, and R. K. Johri, and quot;Piperine inhibits gastric emptying and gastrointestinal transit in rats and mice, and " Planta Medica, vol. 67, no. 2, pp. 176-179, 2001.
72. V. Badmaev, M. Majeed, and E. P. Norkus, and quot;Piperine, an alkaloid derived from black pepper increases serum response of betacarotene during 14-days of oral beta-carotene supplementation, and " Nutrition Research, vol. 19, no. 3, pp. 381-388, 1999.
73. V. Badmaev, M. Majeed, and L. Prakash, and quot;Piperine derived from black pepper increases the plasma levels of coenzyme q10 following oral supplementation, and " The Journal of Nutritional Biochemistry, vol. 11, no. 2, pp. 109-113, 2000.
74. M. H. Kang, S. M. Won, S. S. Park, S. G. Kim, R. F. Novak, and N. D. Kim, and quot;Piperine effects on the expression of P4502E1, P4502B and P4501A in rat, and " Xenobiotica, vol. 24, no. 12, pp. 1195-1204, 1994.
75. R. K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S. K. Gupta, and M. F. Fromm, and quot;Piperine, amajor constituent of black pepper, inhibits human P-glycoprotein and CYP3A4, and " Journal of Pharmacology and ExperimentalTherapeutics, vol. 302, no. 2, pp. 645-650, 2002.
76. G. Sancheti and P. K. Goyal, and quot;Modulatory influence of Rosemarinus officinalis on DMBA-induced mouse skin tumorigenesis, and " Asian Pacific Journal of Cancer Prevention, vol. 7, no. 2, pp. 331-335, 2006.
77. S. N. T. Ngo, D. B. Williams, and R. J. Head, and quot;Rosemary and cancer prevention: preclinical perspectives, and " Critical Reviews in Food Science and Nutrition, vol. 51, no. 10, pp. 946-954, 2011.
78. P. Debersac, J. M. Heydel, M. J. Amiot et al., and quot;Induction of cytochrome P450 and /or detoxication enzymes by various extracts of rosemary: description of specific patterns, and " Food and Chemical Toxicology, vol. 39, no. 9, pp. 907-918, 2001.
79. C. A. Plouzek, H. P. Ciolino, R. Clarke, and G. G. Yeh, and quot;Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract, and " European Journal of Cancer, vol. 35, no. 10, pp. 1541-1545, 1999.
80. Y. Liu, T. J. Flynn, M. S. Ferguson, and E. M. Hoagland, and quot;Use of the combination index to determine interactions between plant-derived phenolic acids on hepatotoxicity endpoints in human and rat hepatoma cells, and " Phytomedicine, vol. 20, no. 5, pp. 461-468, 2013.
81. Y. Pan, B. A. Abd-Rashid, Z. Ismail et al., and quot;In vitro effects of active constituents and extracts ofOrthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes, and " Chemico-Biological Interactions, vol. 190, no. 1, pp. 1-8, 2011.
82. F.-R. Li, Y.-Y. Fu, D.-H. Jiang et al., and quot;Reversal effect of rosmarinic acid on multidrug resistance in SGC7901/Adr cell, and " Journal of Asian Natural Products Research, vol. 15, no. 3, pp. 276-285, 2013.
83. H. J. Kim, Y. J. Chun, J. D. Park, S. I. Kim, J. K. Roh, and T. C. Jeong, and quot;Protection of rat liver microsomes against carbon tetrachloride-lnduced lipid peroxidation by red ginseng, and " Planta Medica, vol. 63, no. 5, pp. 415-418, 1997.
84. C.-T. Yu, J. Chen, X. W. Teng, V. Tong, and T. K. H. Chang, and quot;Lack of evidence for induction of CYP2B1, CYP3A23, and CYP1A2 gene expression by Panax ginseng and Panax quinquefolius extracts in adult rats and primary cultures of rat hepatocytes, and " DrugMetabolism and Disposition, vol. 33, no. 1, pp. 19-22, 2005.
85. T. K. H. Chang, J. Chen, and S. A. Benetton, and quot;In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1, and " Drug Metabolism and Disposition, vol. 30, no. 4, pp. 378-384, 2002.
86. G. L. Henderson, M. R. Harkey, M. E. Gershwin, R. M. Hackman, J. S. Stern, and D. M. Stresser, and quot;Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity, and " Life Sciences, vol. 65, no. 15, pp. L209-L214, 1999.
87. H.-Y. Kwon, E.-H. Kim, S.-W. Kim, S.-N. Kim, J.-D. Park, and D.-K. Rhee, and quot;Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation, and " Archives of Pharmacal Research, vol. 31, no. 2, pp. 171-177, 2008.
88. B. B. Aggarwal and B. Sung, and quot;Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets, and " Trends in Pharmacological Sciences, vol. 30, no. 2, pp. 85-94, 2009.
89. M.-L. Kuo, T.-S. Huang, and J.-K. Lin, and quot;Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells, and " Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1317, no. 2, pp. 95-100, 1996.
90. P. S. Babu and K. Srinivasan, and quot;Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats, and " Molecular and Cellular Biochemistry, vol. 166, no. 1-2, pp. 169-175, 1997.
91. N. Chainani-Wu, and quot;Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa), and " The Journal of Alternative and Complementary Medicine, vol. 9, no. 1, pp. 161-168, 2003.
92. B. B. Aggarwal, A. Kumar, and A. C. Bharti, and quot;Anticancer potential of curcumin: preclinical and clinical studies, and " Anticancer Research, vol. 23, no. 1, pp. 363-398, 2003.
93. W. Zhang, T. M. C. Tan, and L.-Y. Lim, and quot;Impact of curcumininduced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats, and " Drug Metabolism and Disposition, vol. 35, no. 1, pp. 110-115, 2007.
94. N. Romiti, R. Tongiani, F. Cervelli, and E. Chieli, and quot;Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes, and " Life Sciences, vol. 62, no. 25, pp. 2349-2358, 1998.
95. C. S. Yang, T. J. Smith, and J.-Y. Hong, and quot;Cytochrome P-450 enzymes as targets for chemoprevention against chemical carcinogenesis and toxicity: opportunities and limitations, and " Cancer Research, vol. 54, no. 7, supplement, pp. 1982s-1986s, 1994.
96. X.-L. Hou, K. Takahashi, K. Tanaka et al., and quot;Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways, and " International Journal of Pharmaceutics, vol. 358, no. 1-2, pp. 224-229, 2008.
97. X.-L. Hou, K. Takahashi, N. Kinoshita et al., and quot;Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1α, 25 dihydroxyvitamin D3 treated Caco-2 cells, and " International Journal of Pharmaceutics, vol. 337, no. 1-2, pp. 169-177, 2007.
98. P. M. Barnes, B. Bloom, and R. L. Nahin, and quot;Complementary and alternative medicine use among adults and children: United States, 2007, and " National health statistics reports, no. 12, pp. 1-23, 2008.
99. P. A. de Smet, and quot;Clinical risk management of herb-drug interactions, and " British Journal of Clinical Pharmacology, vol. 63, no. 3, pp. 258-267, 2007.